 |
|
A very special patient of mine, Kyle,
passed away from a brainstem glioma at age 7. I founded Presage because
the frequency with which we, as oncologists, unknowingly prescribe therapies
to which our patients’ tumors are already resistant is unacceptable. We need
better approaches to identify drug combinations that will provide benefit
and improve patient survival. Presage is addressing this need in three important
ways: by partnering with pharmaceutical companies to identify effective drug
combinations, partnering with academic researchers to identify preclinical
therapeutics that are “diamonds in the rough” and partnering with oncologists
and their patients to prioritize drugs.
James Olson, M.D., Ph.D
